Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (10): 24-30.doi: 10.6040/j.issn.1671-7554.0.2018.1011
GAO Chunfang, HUANG Chenjun
CLC Number:
| [1] Esnaola NF, Meyer JE, Karachristos A, et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma[J]. Cancer, 2016, 122(9): 1349-1369. [2] Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS- CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5): 261-280. [3] Lafaro KJ, Cosgrove D, Geschwind JF, et al. Multidisciplinary care of patients with intra- hepatic cholangiocarcinoma: updates in management[J]. Gastroenterol Res Pract, 2015, 2015: 860861. doi: 10.1155/2015/860861. [4] Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets[J]. Ann Surg Oncol, 2014, 21(12): 3827-3834. [5] 黄禾, 刘晓蓉, 尤启冬. 异柠檬酸脱氢酶及其突变体抑制剂在急性髓系白血病治疗领域的研究进展[J].药学进展, 2018, 42(3): 207-213. HUANG He, LIU Xiaorong, YOU Qidong.Advances in isocitrate dehydrogenase and the inhibitors of its mutants for acute myeloid leukemia[J]. Progress in Pharmaceutical Sciences, 2018, 42(3): 207-213. [6] Grassian AR, Pagliarini R, Chiang DY, et al. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2014, 30(3): 295-302. [7] Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas[J]. Oncogene, 2013, 32(25): 3091-3100. [8] Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas[J]. Nat Genet, 2013, 45(12): 1470-1473. [9] Grassian AR, Pagliarini R, Chiang D, et al. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma[J]. Curr Opin Gastroenterol, 2014, 30(3): 295-302. [10] Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C)inhibitors allosterically control GTP affinity and effector interactions[J]. Nature, 2013, 503(7477): 548-551. [11] Krasinskas AM, Moser A, Saka B, et al. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas[J]. Mod Pathol, 2013, 26(10): 1346-1354. [12] Xu RF, Sun JP, Zhang SR, et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients[J]. Biomed Pharmacother, 2011, 65(1): 22-26. [13] Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A)alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver[J]. Gut, 2000, 47(5): 721-727. [14] Kennedy L, Baker K, Hodges K, et al. Dysregu- lation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth[J]. Dig Liver Dis, 2013, 45(4): 316-322. [15] Zheng T, Hong X, Wang J, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma[J]. Hepatology, 2014, 59(3): 935-946. [16] Morris SM, Baek JY, Koszarek A, et al. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss[J]. Hepatology, 2012, 55(1): 121-131. [17] O'Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D)and p53 mutation cause primary intrahepatic cholangiocarcinoma[J]. Cancer Res, 2012, 72(6): 1557-1567. [18] Luo G, Li B, Duan C, et al. c-Myc promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway[J]. Oncol Rep, 2017, 38(4): 2498-2506. [19] Songserm N, Promthet S, Sithithaworn P, et al. Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymor- phisms[J]. Cancer Epidemiol, 2012, 36(2): e89-94. [20] Khoontawad J, Pairojkul C, Rucksaken R, et al. Differential protein expression marks the transition from infection with to cholangiocar- cinoma[J]. Mol Cell Proteomics, 2017, 16(5): 911-923. [21] Singh S, Tang SJ, Sreenarasimhaiah J, et al. The clinical utility and limitations of serum carbohydrate antigen(CA19-9)as a diagnostic tool for pancreatic cancer and cholangiocarcinoma[J]. Dig Dis Sci, 2011, 56(8): 2491-2496. [22] Viterbo D, Gausman V, Gonda T, et al. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy[J]. World J Gastrointest Endosc, 2016, 8(3): 128-142. [23] Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935): 2168-2179. [24] Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study[J]. Hepatology, 2000, 31(1): 7-11. [25] Shen WF, Zhong W, Xu F, et al. Clinicopatho-logical and prognosticanalysis of 429 patients with intrahepatic cholangiocarcinoma[J]. World J Gastroenterol, 2009, 15(47): 5976-5982. [26] 徐靖, 易炜, 万百顺. MMP-2和MMP-9在肝内胆管细胞癌组织中的表达及意义[J]. 中国普通外科杂志, 2015, 24(8): 1107-1111. XU Jing, YI Wei, WAN Baishun, etal.MMP-2 and MMP-9 expressions in intrahepatic cholangiocarcinoma tissue and the significance[J] Chinese Journal of General Surgery, 2015, 24(8): 1107-1111. [27] Hirashita T, Iwashita Y, Ohta M, et al. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2012, 16(4): 842-848. [28] Sun Q, Zhao CZ, Xia LZ, et al. High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarci- noma[J]. Int J Clin Exp Pathol, 2014, 7(9): 6157-6164. [29] Tongtawee T, Kaewpitoon SJ, Loyd R, et al. High expression of matrix metalloproteinase-11 indicates poor prognosis in human cholangiocar-cinoma[J]. Asian Pac J Cancer Prev, 2015, 16(9): 3697-3701. [30] Jo Chae K, Rha SY, Oh BK, et al. Expression of matrix metalloproteinase-2 and -9 and tissueinhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductalgrowthtype of cholangiocarcinoma[J]. Am J Gastroenterol, 2004, 99(1): 68-75. [31] Zhang FH, Ren HY, Shen JX, et al. Magnolol suppresses the proliferation and invasion of cholangiocarcinoma cells via inhibiting the NF-κB signaling pathway[J]. Biomed Pharmacother, 2017, 94: 474-480. doi:10.1016/j.biopha.2017.07.085. [32] 张欣, 史若愚, 樊嘉. Dickkopf-1在肝内胆管细胞癌组织及血清中的表达及其临床意义[J].中国临床医学, 2012, 19(2): 102-104. [33] Shen QJ, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multice-ntre study[J]. Lancet Oncol, 2012, 13(8): 817-826. [34] Shi RY, Yang XR, Shen QJ, et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocar- cinoma patients after surgery[J]. Cancer, 2013, 119(5): 993-1003. [35] McGoughIan J, Vincent JP. Exosomes in developmental signalling[J]. Development, 2016, 143(14): 2482-2493. [36] Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2017, 66(4): 1125-1143. [37] Clapéron A, Mergey M, Nguyen HB, et al. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition[J]. J Hepatol, 2014, 61(2): 325-332. [38] Sasaki M, Matsubara T, Yoneda N, et al. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct[J]. Histopathology, 2013, 62(3): 446-457. [39] Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organo- tropic metastasis[J]. Nature, 2015, 527(7578): 329-335. [40] Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcino- ma in mice by an interleukin-6-sensitive mechanism[J]. Hepatology, 2015, 61(5): 1627-1642. [41] Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma[J]. Hepatology, 2013, 58(6): 1992-2000. [42] Lee CT, Wu TT, Lohse CM, et al. High-mobility group AT-hook 2: an independent marker of poor prognosis in intrahepatic cholangiocarcinoma[J]. Hum Pathol, 2014, 45(11): 2334-2340. [43] Huang L, ChenW, Liang P, et al. Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma[J]. Dig Dis Sci, 2015, 60(5): 1273-1283. [44] Lau KS, Dennis JW. N-Glycans in cancer progression[J]. Glycobiology, 2008, 18(10): 750-760. [45] Matsuda A, KunoAtsushi,Kawamoto Toru,et al. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma[J]. Hepatology, 2010, 52(1): 174-182. [46] Matsuda A, Kuno A, Matsuzaki H, et al. Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma[J]. J Proteomics, 2013, 85: 1-11. doi: 10.1016/j.jprot.2013.04.017. [47] Indramanee S, Silsirivanit A, Pairojkul C, et al. Aberrant glycosylation in cholangiocarcinoma demonstrated by lectin-histochemistry[J]. Asian Pac J Cancer Prev, 2012, 13(Suppl): 119-124. [48] Saentaweesuk W, Silsirivanit A, Vaeteewoottacharn K, et al. Clinical significance of GalNAcylated glycans in cholangiocarcinoma: Values for diagnosis and prognosis[J]. Clin Chim Acta, 2018, 477: 66-71. doi: 10.1016/j.cca.2017.12.005. |
| [1] | LV Yan-Feng, DING Ke, WANG Jian-Xin, YU Hua-Long, BEI Shao-Sheng. Canceration of chronic anal fistula [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 55-57. |
| [2] | LI Bo-Bo, LI Dao-Tang, LIU Shu-Guang, WANG Xing-Wu. Expression of serum DKK-1 in esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 58-61. |
| [3] | XU Ping, YU Guo-Fang, LI Xia. Differential diagnosis of Graves′ disease and Hashimoto′s thyroiditis by different types peak systolic velocity of the superior thyroid artery [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 62-64. |
| [4] | WANG Xin, XING Chun-Yan, YANG Yan-Ping. Serum phosphopyruvate hydratase in diagnosis of invasive Candida albicans infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 92-94. |
| [5] | ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96. |
| [6] | WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112. |
| [7] | HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43. |
| [8] | JIANG Ziqing, ZENG Yanping, JI Xiaodong, ZUO Junling. A case report of hemophagocytic syndrome secondary to talaromyces marneffei infection [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 91-97. |
| [9] | ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122. |
| [10] | LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58. |
| [11] | ZHANG Jingliang, LIU Xinyu, YUAN Suomao, WANG Lianlei. Causes of misdiagnosis and mistreatment of lumbar degenerative diseases complicated with hip joint diseases(hip-spine syndrome) [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 67-73. |
| [12] | SONG Min, ZHOU Yuxia, GAO Lu, LIU Na, WANG Ju, GU Jin, ZHANG Yanping. Prenatal diagnosis for a fetus of mosaic trisomy 6q [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 109-113. |
| [13] | ZUO Liping, JIANG Fengyang, ZHOU Binbin, FAN Jinlei, LIANG Yongfeng, DENG Zhanhao, YU Dexin. Value of preoperative multiphase MRI for predicting microvascular invasion and early recurrence of 169 hepatocellular carcinoma [J]. Journal of Shandong University (Health Sciences), 2022, 60(3): 89-95. |
| [14] | SONG Yufeng, NING Hao, YAO Zhigang, WU Haihu, LIU Feifan, LYU Jiaju. Clinical and imaging features of adrenal cavernous hemangioma [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 37-42. |
| [15] | PAN Pengfei, XU Lisheng, JI Kunqian, WANG Dexiang, LI Yu. Mitochondrial myopathy beginning with respiratory failure: one case and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 54-59. |
|
||
